-

nihao guest [ sign in / register ]
2026-11-22 19:16:53


McClain, M.T., Bryant, C., Culverhouse-Steadman, C. A multicenter, dose-ranging human challenge study of a recombinant influenza A (A/Texas/71/2017 (H3N2)) virus in healthy adult volunteers. npj Vaccines (2026)
submited by kickingbird at Nov, 22, 2026 9:44 AM from npj Vaccines (2026)

Controlled human infection models (CHIM) provide a crucial platform for evaluating influenza countermeasures. This dose-escalation, double-blind, randomized, placebo-controlled study aimed to establish the optimal infectious dose of a recombinant influenza A/Texas/71/2017 (H3N2) challenge strain. Healthy adults aged 18–45 received sham inoculum or 10?, 10?, or 10? median tissue culture infectious dose (TCID??) of challenge virus and were monitored for 7 days. The primary endpoint, attack rate (AR), required solicited symptoms combined with RT-PCR-confirmed viral shedding on ≥2 days. Mucosal and serum antibodies were measured to evaluate baseline and post-challenge immune responses. Following challenge, AR scaled with inoculum with 33.3% (10? TCID??; n?=?4/12), 50.0% (10? TCID??; n?=?5/10), and 77.8% (10? TCID??; n?=?28/36) meeting the primary endpoint. Symptoms began and peaked earlier in the 106 group, while peak and total viral shedding were higher in, but similar between, the 105 and 106 groups. Baseline serum IgG (HA and MN) and nasal secretory IgA (HA) levels were lower in participants who developed symptomatic infection, though high inter-individual variability limited their utility as predictive correlates of susceptibility. AEs were uncommon and typically mild, and no serious adverse events occurred. Controlled human challenge with A/Texas/71/2017 (H3N2) demonstrated a maximal and efficient AR at the highest challenge dose of 106 TCID50 with no apparent effect on safety. Challenge with 106 TCID50 of this influenza stain offers strong potential as an efficient model for evaluating future influenza countermeasures.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


  

Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
Copyright ©www.flu.org.cn. 2004-2026. All Rights Reserved. Powered by FIC 4.0.1
  Email:webmaster@flu.org.cn